| 前收市價 | 128.64 |
| 開市 | 127.16 |
| 買盤 | 0.00 x 1200 |
| 賣出價 | 0.00 x 1000 |
| 今日波幅 | 125.35 - 127.32 |
| 52 週波幅 | 75.56 - 138.28 |
| 成交量 | |
| 平均成交量 | 5,050,317 |
| 市值 | 562.841B |
| Beta 值 (5 年，每月) | 0.19 |
| 市盈率 (最近 12 個月) | 47.43 |
| 每股盈利 (最近 12 個月) | 2.66 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 1.37 (1.09%) |
| 除息日 | 2024年3月22日 |
| 1 年預測目標價 | 144.57 |
ZacksNovo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day.
- Reuters
US Senate committee investigates pricing of Novo's Ozempic and Wegovy
A U.S. Senate committee said on Wednesday it had launched an investigation into the prices of Novo Nordisk's diabetes and weight loss drugs Ozempic and Wegovy in the United States. Senator Bernie Sanders, chair of the Senate Committee on Health, Education, Labor and Pensions, sent a letter to Novo's CEO seeking more information on U.S. prices for the two drugs, which are higher than the prices in other countries. The committee also asked Novo if it will substantially reduce both the list price and the net price of both the drugs, and why the company was charging a higher price for the weight loss drug Wegovy than Ozempic, which contains the same compound.
Investor's Business DailyWeight Loss Leader Novo Nordisk Hits Buy Trigger In Stock Market Rebound
Novo Nordisk stock: The weight-loss drug leader hit a buy point in the recent stock market rebound and is one of the best stocks to watch.
